Stay current with the latest press releases from within the industry.
Release issued 21st December 2001
MONTREAL, Quebec, December 21, 2001 - ConjuChem Inc. (TSE:CJC), developers of the drug-enabling DAC(tm) technology, today announced a sponsored research collaboration agreement with Almirall Prodesfarma, a leading pharmaceutical company based in Barcelona, Spain to research an expanded indication for DAC:TI' (CJC-1004). Currently, ConjuChem is investigating the use of DAC:TI' for the prevention of localized blood clotting in kidney dialysis patients with arterio-venous shunts.
The agreement allows Almirall Prodesfarma to conduct pre-clinical efficacy studies with DAC:TI' over a 6-month period. In addition, Almirall Prodesfarma has the option to enter into exclusive negotiations for a development and commercial license to DAC:TI' during the option period. ConjuChem has received an option payment as per the terms of this research collaboration.
DAC:TI(tm) is derived from argatroban, a thrombin inhibitor recently approved in the USA for certain anti-coagulant (anti-clotting) indications. Thrombin inhibitors are a class of anti-coagulant drugs that prevent thrombin formation, the final step in the coagulation cascade. Using ConjuChem's local DAC(tm) Technology, argatroban is engineered into a drug construct (CJC-1004) designed to be locally administered at a vascular site in the body that is at high risk of developing blood clots. Upon administration, DAC:TI(tm) covalently bonds (bioconjugates) to the proteins in the tissues at the local site of administration. The tissue bioconjugate thus formed has similar potency to argatroban and is expected to have a high level of localized anti-clotting activity with a biological activity duration of days to weeks, without the systemic side-effects encountered with most anti-coagulant medications. DAC:TI(tm) is scheduled to commence Phase II trials in the second quarter of 2002.
If you want to find out more about the company visit ConjuChem Biotechnologies profile.
(8th August 2002) ConjuChem Discontinues DAC(tm):TI Development
(13th May 2002) ConjuChem Completes Phase I DAC:TI Patient Enrolment
Clients in focus...